2025 Newsmaker: David Ricks
As of Nov. 13, Eli Lilly and Co.’s market capitalization was $967 billion and flirting with a rare $1 trillion. Its stock price in November surpassed $1,000 per share, up more than 25% for the year.
Eli Lilly and Co.
-
Lilly, IU sign clinical trial, research agreement worth up to $40M
Officials say the pact, facilitated by the Indianapolis-based IU Launch Accelerator for Biosciences, is the largest single industry-sponsored agreement in the school’s history.
Read More -
Lilly, Nvidia team up to build pharma’s ‘most powerful’ supercomputer
The Indianapolis-based drugmaker said the supercomputer will power an “AI factory” designed to accelerate drug discovery and development.
Read More -
Q&A with the head of Lilly manufacturing, who meticulously tracks gains in work, life
“People come together, operators, with their supervisors at 6 a.m. every morning, and they talk about what issues they have and how they propose to solve it. Those get escalated through all levels of management.”
Read More -
Eli Lilly to spend $27B on four new manufacturing sites
The new manufacturing sites are expected to create create 3,000 pharmaceutical jobs and nearly 10,000 construction positions during the buildout.
Read More
Articles
US regulators approve Wegovy pill for weight loss, giving Novo Nordisk an edge over Lilly
Novo Nordisk’s Wegovy pills are expected to be available within weeks, while Indianapolis-based Eli Lilly and Co. waits for approval for its daily GLP-1 pill, orforglipron.
Lilly’s growth explosion tests state’s workforce development
Eli Lilly and Co.’s career website this month listed 254 job openings in Indianapolis and another 90 in Lebanon, accounting for more than three-quarters of the 445 open positions the pharmaceutical giant listed across the United States.
Lilly Phase 3 trial shows GLP-1 pill effective for weight-loss maintenance
According to the study, orforglipron users maintained their weight loss levels more closely after previously taking a rival’s GLP-1 injectable, the Indianapolis-based drugmaker said.
Lilly to build $6B plant in Alabama in 3rd of 4 big US investments
Lilly’s planned Huntsville site is part of the drugmaker’s commitment to add four U.S. manufacturing sites through a $27 billion reshoring investment unveiled early this year.
Lilly cuts prices on Zepbound vials sold on LillyDirect
The decision is the latest in a series of moves to make its GLP-1 blockbuster more widely available and affordable.
Lilly rolling out direct-to-employer obesity drug coverage
The Indianapolis-based drugmaker said the coverage would be administered by third-party administrators to provide employers “transparent, flexible cost-sharing options” for their workers.
Lilly joins $1 trillion club as weight-loss drugs fuel stock surge
It’s just the latest landmark for Indianapolis-based Lilly, which was catapulted into the top spot as the world’s largest health care company by market capitalization in 2023.
Lilly to open Gateway Labs site in Philadelphia
Since the first biotech incubator site opened in 2019, participating startups have collectively raised more than $3 billion.
The surprising new use for GLP-1s: Alcohol and drug addiction
As GLP-1 drugs for weight loss and diabetes drugs such as Zepbound and Mounjaro generate billions in sales, researchers at Eli Lilly and Co. and other pharma companies are exploring their potential for other purposes.
Lilly CEO calls on state to boost power supply as company seeks to build supercomputer
David Ricks, speaking Thursday during a panel at the annual BioCrossroads Life Sciences Summit, also called for Purdue and Indiana universities to upgrade their lab facilities.
UPDATE: Eli Lilly stock reaches new high, tops $1,000-per-share mark
Lilly’s shares have taken off in the wake of several significant deals and after it received fast-track regulatory review for highly anticipated weight-loss pill orforglipron.
Lilly’s obesity pill, orforglipron, gets FDA fast-track voucher
The announcement comes on the heels of a deal with the Trump administration to expand access to weight-loss drugs and reduce costs for patients on government-funded insurance and those paying out of pocket.
Trump unveils deal with Lilly, Novo to expand coverage, lower costs on obesity drugs
Thursday’s announcement is the latest attempt by the Trump administration to rein in soaring drug prices in its efforts to address cost-of-living concerns among voters.
UPDATE: White House nears deal with Lilly, Novo to slash obesity drug prices for Medicare
The deal is seen as one of the most significant in the administration’s current drug-pricing push, given the potential effect on public health and spending on health care.
Eli Lilly to build $3B manufacturing site in Netherlands
The facility is expected to produce oral medications, including Lilly’s highly anticipated GLP-1 pill for weight loss, orforglipron.
IU-Lilly study to explore drugs’ impact on job productivity
Eli Lilly and Co. is funding and participating in an Indiana University study that examines the health outcomes of people on weight loss drugs, including Lilly medications.
Lilly earnings soar on growth of Mounjaro, Zepbound
With quarterly revenue up 54% from a year ago, Eli Lilly raised it guidance for the year, with the company now expecting revenue in the range of $63 billion to $63.5 billion.
Lilly expands Zepbound direct-to-patient access through Walmart partnership
Through its LillyDirect pharmacy, Eli Lilly plans to offer steep discounts on single-dose vials of Zepbound by partnering with the nation’s largest retail chain.
Lilly plans $1.2B expansion in Puerto Rico, adding 100 manufacturing jobs
Indianapolis-based Eli Lilly and Co. said the improved facility in Carolina, Puerto Rico, will make orforglipron, Lilly’s highly anticipated weight loss pill.